Validation of the Patient-Oriented SCORing for Atopic Dermatitis tool for black skin.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
02
04
2019
accepted:
05
09
2019
pubmed:
7
10
2019
medline:
30
1
2021
entrez:
7
10
2019
Statut:
ppublish
Résumé
SCORing for Atopic Dermatitis (SCORAD) is a tool developed by the European Task Force on Atopic Dermatitis (AD) which is used by physicians to assess AD severity during consultations with their patients. Patient-Oriented SCORAD (PO-SCORAD) is a self-assessment tool for use by patients which has been validated in a study performed in European countries. However, there is currently no adapted tool for evaluating AD severity in black skin. To evaluate the performance of the version of the PO-SCORAD specifically adapted for black skin patients (children and adults) with AD. In this multicenter, cross-sectional and non-interventional study, children and adults with AD were recruited during regular consultations. This international study was performed in seven sub-Saharan countries (Benin, Burkina Faso, Cameroon, Ivory Coast, Gabon, Mali and Senegal). During the consultation, AD severity was assessed by the physician using SCORAD score and by the patients or parents using PO-SCORAD. One hundred and thirteen patients were included, 72 children and 41 adults, mainly females (61.6%). SCORAD assessed by physicians and PO-SCORAD assessed by patients/parents were well correlated (r = 0.66, P < 0.0001). Correlation coefficients for SCORAD and PO-SCORAD subscale scores were also good, except for symptom intensity criteria. Altogether, these data indicate that PO-SCORAD for black skin correlates well with SCORAD and is therefore a valuable tool, which requires no specific level of education, for use by black skin patients with AD.
Sections du résumé
BACKGROUND
BACKGROUND
SCORing for Atopic Dermatitis (SCORAD) is a tool developed by the European Task Force on Atopic Dermatitis (AD) which is used by physicians to assess AD severity during consultations with their patients. Patient-Oriented SCORAD (PO-SCORAD) is a self-assessment tool for use by patients which has been validated in a study performed in European countries. However, there is currently no adapted tool for evaluating AD severity in black skin.
OBJECTIVE
OBJECTIVE
To evaluate the performance of the version of the PO-SCORAD specifically adapted for black skin patients (children and adults) with AD.
METHODS
METHODS
In this multicenter, cross-sectional and non-interventional study, children and adults with AD were recruited during regular consultations. This international study was performed in seven sub-Saharan countries (Benin, Burkina Faso, Cameroon, Ivory Coast, Gabon, Mali and Senegal). During the consultation, AD severity was assessed by the physician using SCORAD score and by the patients or parents using PO-SCORAD.
RESULTS
RESULTS
One hundred and thirteen patients were included, 72 children and 41 adults, mainly females (61.6%). SCORAD assessed by physicians and PO-SCORAD assessed by patients/parents were well correlated (r = 0.66, P < 0.0001). Correlation coefficients for SCORAD and PO-SCORAD subscale scores were also good, except for symptom intensity criteria.
CONCLUSION
CONCLUSIONS
Altogether, these data indicate that PO-SCORAD for black skin correlates well with SCORAD and is therefore a valuable tool, which requires no specific level of education, for use by black skin patients with AD.
Identifiants
pubmed: 31587383
doi: 10.1111/jdv.15999
pmc: PMC7154547
doi:
Types de publication
Journal Article
Multicenter Study
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
795-799Subventions
Organisme : Pierre Fabre Dermatologie
Informations de copyright
© 2019 PIERRE FABRE DERMATOLOGIE. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Br J Dermatol. 2020 Jan;182(1):104-111
pubmed: 30972740
Allergy. 2007 Mar;62(3):247-58
pubmed: 17298341
Clin Dermatol. 2018 Sep - Oct;36(5):595-605
pubmed: 30217272
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
Lancet. 2003 Jan 11;361(9352):151-60
pubmed: 12531593
Br J Dermatol. 1994 Sep;131(3):406-16
pubmed: 7918017
J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38
pubmed: 9893196
Allergy. 2011 Aug;66(8):1114-21
pubmed: 21414011
Dermatology. 1997;195(1):10-9
pubmed: 9267730
Lancet. 2006 Aug 26;368(9537):733-43
pubmed: 16935684
J Epidemiol Community Health. 2000 Aug;54(8):581-9
pubmed: 10890869
Dermatology. 2014;229(3):248-55
pubmed: 25196258
Dermatology. 1993;186(1):23-31
pubmed: 8435513
Allergy Asthma Proc. 2008 Jul-Aug;29(4):392-6
pubmed: 18702887
Dermatology. 2009;218(3):246-51
pubmed: 19147989